Diabetic retinopathy: an Indian perspective.
Diabetic retinopathy (DR) can be defined as damage to microvascular system in the retina due to prolonged hyperglycaemia. The prevalence of DR in the Chennai Urban Rural Epidemiology (CURES) Eye Study in south India was 17.6 per cent, significantly lower than age-matched western counterparts. However, due to the large number of diabetic subjects, DR is likely to pose a public health burden in India. CURES Eye study showed that the major systemic risk factors for onset and progression of DR are duration of diabetes, degree of glycaemic control and hyperlipidaemia. Hypertension did not play a major role in this cross-sectional analysis. The role of oxidative stress, atherosclerotic end points and genetic factors in susceptibility to DR has been studied. It was found that DR was associated with increased intima-media thickness and arterial stiffness in type 2 Indian diabetic subjects suggesting that common pathogenic mechanisms might predispose to diabetic microangiopathy. Curcumin, an active ingredient of turmeric, has been shown to inhibit proliferation of retinal endothelial cells in vivo. Visual disability from DR is largely preventable if managed with timely intervention by laser. It has been clearly demonstrated that in type 2 south Indian diabetic patients with proliferative DR who underwent Pan retinal photocoagulation, 73 per cent eyes with good visual acuity (6/9) at baseline maintained the same vision at 1 yr follow up. There is evidence that DR begins to develop years before the clinical diagnosis of type 2 diabetes. Our earlier study demonstrated that DR is present in 7 per cent of newly diagnosed subjects, hence routine retinal screening for DR even at the time of diagnosis of type 2 diabetes may help in optimized laser therapy. Annual retinal examination and early detection of DR can considerably reduce the risk of visual loss in diabetic individuals.
Rema
M
M
Madras Diabetes Research Foundation & Dr Mohan's Diabetes Specialities Centre, Chennai, India. drrema@vsnl.com
Pradeepa
R
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D007194:India / Q000453:epidemiology; D015995:Prevalence; D012424:Rural Population; D014505:Urban Population
D020533:Angiogenesis Inhibitors; D000925:Anticoagulants